BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Fireside chat details: |
|
Date: | Thursday, September 28, 2023 |
Time: | 12:40 – 1:10 p.m. Eastern Standard Time (EST) |
Moderator: | Pete Stavropoulos, Ph.D. |
Location: | Intercontinental Barclay Hotel, New York |
HilleVax Participant: | Aditya Kohli, Ph.D., Chief Operating Officer |
Webcast & Audit Visual: | https://wsw.com/webcast/cantor19/hlvx/2124738 |
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute ...